scholarly journals Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation

Lung Cancer ◽  
2021 ◽  
Author(s):  
Pablo Moreno-Ruiz ◽  
Sara Corvigno ◽  
Nienke C. te Grootenhuis ◽  
Linnéa La Fleur ◽  
Max Backman ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Poor Prognosis ◽  
P53 Mutation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Prognosis Marker

scholarly journals Cell division cycle 20 overexpression predicts poor prognosis for patients with lung adenocarcinoma

Tumor Biology ◽  
2017 ◽  
Vol 39 (3) ◽  
pp. 101042831769223 ◽  
Author(s):  
Run Shi ◽  
Qi Sun ◽  
Jing Sun ◽  
Xin Wang ◽  
Wenjie Xia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Division ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Tumor Size ◽  
Poor Prognosis ◽  
Small Cell ◽  
Cell Division Cycle ◽  
Small Cell Lung

The cell division cycle 20, a key component of spindle assembly checkpoint, is an essential activator of the anaphase-promoting complex. Aberrant expression of cell division cycle 20 has been detected in various human cancers. However, its clinical significance has never been deeply investigated in non-small-cell lung cancer. By analyzing The Cancer Genome Atlas database and using some certain online databases, we validated overexpression of cell division cycle 20 in both messenger RNA and protein levels, explored its clinical significance, and evaluated the prognostic role of cell division cycle 20 in non-small-cell lung cancer. Cell division cycle 20 expression was significantly correlated with sex (p = 0.003), histological classification (p < 0.0001), and tumor size (p = 0.0116) in non-small-cell lung cancer patients. In lung adenocarcinoma patients, overexpression of cell division cycle 20 was significantly associated with bigger primary tumor size (p = 0.0023), higher MKI67 level (r = 0.7618, p < 0.0001), higher DNA ploidy level (p < 0.0001), and poor prognosis (hazard ratio = 2.39, confidence interval: 1.87–3.05, p < 0.0001). However, in lung squamous cell carcinoma patients, no significant association of cell division cycle 20 expression was observed with any clinical parameter or prognosis. Overexpression of cell division cycle 20 is associated with poor prognosis in lung adenocarcinoma patients, and its overexpression can also be used to identify high-risk groups. In conclusion, cell division cycle 20 might serve as a potential biomarker for lung adenocarcinoma patients.

Over-Expression of Egfr is Closely Correlated to Poor Prognosis in Tunisian Patients with Non-Small Cell Lung Adenocarcinoma

2014 ◽  
Vol 35 (3) ◽  
pp. 256-268 ◽  
Author(s):  
Amira Arfaoui ◽  
Lilia Kriaa ◽  
Nadia Znaidi ◽  
Sami Gritli ◽  
Hend Bouacha ◽  
...  
Keyword(s):  
Lung Adenocarcinoma ◽  
Poor Prognosis ◽  
Small Cell ◽  
Small Cell Lung ◽  
Over Expression ◽  
Tunisian Patients

scholarly journals Increased KIF15 Expression Predicts a Poor Prognosis in Patients with Lung Adenocarcinoma

2018 ◽  
Vol 51 (1) ◽  
pp. 1-10 ◽  
Author(s):  
Yuan Qiao ◽  
Jingtao Chen ◽  
Chao Ma ◽  
Yingmin Liu ◽  
Peitong Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Cycle ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Messenger Rna ◽  
Poor Prognosis ◽  
Human Lung ◽  
Small Cell ◽  
Small Cell Lung ◽  
Protein Levels

Background/Aims: Lung cancer is the leading cause of cancer-related deaths worldwide. The outcome of patients with non-small cell lung cancer remains poor; the 5-year survival rate for stage IV non-small cell lung cancer is only 1.0%. KIF15 is a tetrameric kinesin spindle motor that has been investigated for its regulation of mitosis. While the roles of kinesin motor proteins in the regulation of mitosis and their potentials as therapeutic targets in pancreatic cancer have been described previously, the role of KIF15 in lung cancer development remains unknown. Methods: Paired lung carcinoma specimens and matched adjacent normal tissues were used for protein analysis. Clinical data were obtained from medical records. We first examined KIF15 messenger RNA expression in The Cancer Genome Atlas database, and then determined KIF15 protein levels using immunohistochemistry and western blotting. Differences between the groups were analyzed using repeated measures analysis of variance. Overall survival was analyzed using the Kaplan–Meier method. Cell-cycle and proliferation assays were conducted using A549, NCI-H1299, and NCI-H226 cells. Results: KIF15 was significantly upregulated at both the messenger RNA and protein levels in human lung tumor tissues. In patients with lung adenocarcinoma, KIF15 expression was positively associated with disease stages; high KIF15 expression predicted a poor prognosis. KIF15 knockdown using short hairpin RNA in two human lung adenocarcinoma cell lines induced G1/S phase cell cycle arrest and inhibited cell growth, but there was no effect in human lung squamous cell carcinoma. Conclusion: Our findings show that KIF15 is involved in lung cancer carcinogenesis. KIF15 could therefore serve as a specific prognostic marker for patients with lung adenocarcinoma.

scholarly journals Screening prognostic markers for non-small cell lung cancer based on data mining and bioinformatics analysis

2020 ◽  
Author(s):  
Bin Han ◽  
Kaushik Chandra Aman ◽  
Dongqing Wei ◽  
Shulin Zhang ◽  
Minjie Meng
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Small Cell Lung Cancer ◽  
Differentially Expressed Genes ◽  
Cell Lung Cancer ◽  
Poor Prognosis ◽  
Prognostic Markers ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung

Abstract Background At present, non-small cell lung cancer has a high morbidity and mortality, and the recurrence and metastasis situation is serious. It is impossible to accurately predict the prognosis of cancer patients clinically. Biomarker is a kind of biomolecule with wide application prospects, and its potential in cancer prognosis is gradually revealed, and it is expected to be applied clinically. Results We integrated four gene expression profiles (GSE19188, GSE19804, GSE101929 and GSE18842) from the GEO database and screened the commonly differentially expressed genes using the GEO2R online tool. We screened 952 commonly differentially expressed genes. Gene ontology analysis showed that CDEGs were mainly enriched in biological processes such as cell adherin, angiogenesis and positive regulation of angiogenesis, and KEGG pathways such as ECM-receptor interaction and cell adherin molecules (CAMs). Up-regulation of G2 and S phase-expressed protein 1(GTSE1) expression is associated with poor prognosis of lung adenocarcinoma(LADE) and lung squamous cell carcinoma(LUSC). Up-regulation of Neuromedin-U(NMU) expression, down-regulation of Proto-oncogene c-Fos(FOS) and Cyclin-dependent kinase inhibitor 1C(CDKN1C) is only associated with poor prognosis of LADE. Conclusions We believe that GTSE1, NMU, FOS, and CDKN1C have potential application value as prognostic markers for lung adenocarcinoma, and are of great significance for lung adeno carcinoma efficacy evaluation and relapse monitoring. At the same time, GTSE1 may also be used as a new target for cancer treatment New ways.

ROS1-rearranged lung adenocarcinoma with peritoneal carcinomatosis on initial presentation

2020 ◽  
Vol 13 (3) ◽  
pp. e233864
Author(s):  
Vera Kazakova ◽  
Sylvia V Alarcon Velasco ◽  
Aleksandr Perepletchikov ◽  
Christopher S Lathan
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Peritoneal Carcinomatosis ◽  
Poor Prognosis ◽  
Primary Tumour ◽  
Small Cell ◽  
Small Cell Lung ◽  
Peritoneal Spread ◽  
New Onset

Peritoneal carcinomatosis (PC) is progression of the primary cancer to the peritoneum that is seen in only 1.2% of patients with lung cancer. It is associated with poor prognosis especially if present at the time of initial cancer diagnosis. The predisposing factors for peritoneal spread are not yet well understood. It has been suggested that the oncogene status of the tumour can influence the patterns of metastatic spread. There is not enough data about the role of c-ROS oncogene 1 (ROS1) mutation in the development of PC in non-small cell lung cancer. Here, we describe a case of a 56-year-old man who presented with new-onset ascites and was found to have PC. He was diagnosed with ROS1-rearranged lung adenocarcinoma. No obvious primary tumour was identified. Patient responded well to targeted therapy with crizotinib and remained 6 months free of disease progression.

The tyrosine kinase TEK is differentially expressed in non-small cell lung adenocarcinomas.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
United States ◽  
Tyrosine Kinase ◽  
Lung Adenocarcinoma ◽  
Microarray Data ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Significant Differential Expression ◽  
Lung Cancers ◽  
Lung Adenocarcinomas

Non-small cell lung adenocarcinoma (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the tyrosine kinase TEK in tumors from patients with NSCLC. TEK may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.

Sign in / Sign up

Export Citation Format

Share Document